Business Context and Reporting Period
This Form 8-K, filed on June 18, 2024, reports events occurring on June 13, 2024, and June 17, 2024, for Spruce Biosciences, Inc. (SPRB). The filing details the Company's participation in a bankruptcy court-supervised auction process to acquire assets from Eiger BioPharmaceuticals, Inc., specifically relating to the drug candidate Avexitide.
Key Financial Metrics and Transaction Details
This filing does not report standard periodic financial metrics such as revenue, profit, cash flow, or operating margins. The financial data presented is specific to a potential asset acquisition:
- Initial Stalking Horse Bid: $10.0 million (subject to adjustments).
- Back-Up Bid Amount: $35.0 million gross.
- Net Back-Up Purchase Price: $34.7 million (after a $0.3 million credit for the termination fee).
- Additional Obligations: Assumption of specified contractual cure amounts up to $0.3 million.
- Termination Fee: $0.3 million payable to Spruce if the primary sale fails and Spruce is not required to close.
Material Changes and Transaction Status
The Company entered into a "stalking horse" asset purchase agreement on June 13, 2024. Following an auction on June 17, 2024, Spruce was designated as the back-up bidder rather than the winning bidder. The transaction remains subject to approval by the United States Bankruptcy Court for the Northern District of Texas at a hearing scheduled for June 26, 2024. If the winning bidder fails to consummate the acquisition, Spruce is obligated to close the deal at the back-up price; otherwise, Spruce receives the termination fee.
Outlook, Risks, and Contingencies
The completion of the asset acquisition is contingent upon Bankruptcy Court approval and the failure of the winning bidder to close the transaction. Management notes that forward-looking statements regarding the sale are subject to risks and uncertainties, including general business risks, geopolitical events, and macroeconomic factors. The filing explicitly states that actual results may differ materially from expectations.
Investor Verification Checklist
- Verify the outcome of the Bankruptcy Court hearing scheduled for June 26, 2024, regarding the sale of the Transferred Assets.
- Confirm whether the winning bidder successfully consummates the acquisition, which would trigger Spruce's receipt of the $0.3 million termination fee.
- Review the full Asset Purchase Agreement (Exhibit 10.1) for specific adjustments, covenants, and definitions of the Transferred Assets.
- Monitor subsequent filings for any updates on the assumption of contractual cure amounts or changes in the back-up bid status.